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GB virus C (GBV-C; also called hepatitis G virus) is a common cause of infection associated with prolonged
survival among HIV-infected individuals. The prevalences of GBV-C viremia vary widely in different studies,
and there has been poor agreement among different laboratories performing GBV-C RNA detection in quality
control studies. To determine the optimal method of measuring GBV-C RNA in clinical samples, samples
obtained from 939 HIV-infected subjects were studied using reverse transcription (RT)-PCR methods ampli-
fying four separate regions of the GBV-C genome. Primers amplifying the E2 coding region were 100% specific;
however, their sensitivity was only 76.6%. In contrast, primers amplifying three additional conserved regions
of the GBV-C genome (the 5 nontranslated region and the nonstructural protein-coding regions 3 and 5A)
were more sensitive but produced higher rates of false-positive results. Using low-specificity primer sets
influenced the significance of association between GBV-C viremia and response to antiretroviral therapy. Using
a quantitative GBV-C RNA method, the GBV-C RNA concentration did not correlate with baseline or set point
HIV RNA levels; however, a correlation between negative, low, and high GBV-C RNA levels and increasing
reduction in HIV RNA following antiretroviral therapy was observed. Subjects with both GBV-C E2 antibody
and viremia had significantly lower GBV-C RNA levels than did viremic subjects without E2 antibody. These
studies demonstrate that accurate detection of GBV-C RNA by nested RT-PCR requires the use of primers
representing multiple genome regions. Analyses based on testing with single primers do not lead to reliable
conclusions about the association between GBV-C infection and clinical outcomes.
GB virus type C (GBV-C, also called hepatitis G virus) is
classified within the family Flaviviridae and is the human virus
most closely related to hepatitis C virus (17, 24). GBV-C con-
tains a single-stranded, positive-sense RNA genome encoding
a long polyprotein that is proteolytically cleaved into structural
and nonstructural proteins (reviewed in reference 26). Epide-
miologic studies have failed to identify any association between
GBV-C and acute or chronic hepatitis or any other human
disease (reviewed in references 2 and 19). Although GBV-C
viremia may persist for decades in some infected humans, the
majority of immune-competent individuals clear GBV-C RNA
and thereafter have detectable antibody to the GBV-C surface
envelope glycoprotein E2 (26). The presence of E2 antibody is
associated with decreased risk of subsequent transfusion-re-
lated infection with GBV-C (29, 31), suggesting that E2 anti-
bodies possess neutralizing activity.
Due to shared modes of transmission (7, 8, 10, 16, 22, 34),
GBV-C infection is common in human immunodeficiency virus
(HIV)-infected people (20, 27, 36), with active viremia or ev-
idence of past infection (E2 antibody) present in as many as
86% (33). Active viremia with GBV-C has been detected by
reverse transcription (RT)-PCR methods in 17% (9) to 43%
(20) of HIV-positive individuals. In several, though not all,
studies, HIV-infected people who were coinfected with
GBV-C had decreased mortality (9, 14, 30, 33, 36, 37) and
favorable clinical markers of HIV disease progression (30, 33,
37) compared to those without GBV-C viremia. A meta-anal-
ysis found a highly significant association with prolonged sur-
vival in HIV-infected individuals when GBV-C RNA was de-
tected five or more years following HIV infection (39). In
addition, several, though not all, studies found an association
between GBV-C viremia and improved response to antiretro-
viral therapy (ART) (3, 6, 21, 25).
GBV-C viremia is measured by detecting viral RNA in se-
rum or plasma using RT-PCR methods designed to amplify
conserved sequences of the viral genome. Early studies of
RT-PCR detection of GBV-C utilized primers that amplified
the nonstructural-protein-coding regions 3 and 5A (NS3 and
NS5A) (5, 12, 15); however, most subsequent studies have used
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primers that amplified the conserved 5 nontranslated region
(5 NTR) of the genome (6, 9, 14, 21, 36, 37). We previously
designed primers to amplify two regions of the 5 NTR, the 3
nontranslated region, the two envelope glycoprotein-coding
regions (E1 and E2), and five nonstructural-protein-coding
regions (NS2, NS3, NS4, NS5A, and NS5B) (J. Xiang, F. La-
Brecque, W. N. Schmidt, D. Klinzman, D. Brashear, D. R.
LaBrecque, M. J. Perino-Phillips, and J. T. Stapleton, pre-
sented at the Tenth Triennial International Symposium on
Viral Hepatitis and Liver Disease, 9 to 14 April 2000, Atlanta,
GA). Using these primers to detect GBV-C viremia in patients
with hepatitis C virus and GBV-C coinfection, we found that
RT-PCR using primers representing the E2 protein-coding
region and the 5 nontranslated region of the genome provided
equal sensitivity, although the E2 primers provided more con-
sistent results. Consequently, we and others used primers am-
plifying a portion of the E2 protein-coding region in several
epidemiological studies of GBV-C and HIV coinfection (11,
23, 32, 33, 38).
In a recent study, different estimates of GBV-C prevalences
were found when sera were tested by RT-PCR methods em-
ploying E2 and 5-NTR primers (I. E. Souza, W. Zhang, R. S.
Diaz, K. Chaloner, D. Klinzman, and J. T. Stapleton, presented
at the Infectious Disease Society of America annual meeting,
Boston, MA, 28 to 30 September 2004), suggesting that the
specific primers selected to amplify GBV-C RNA might pro-
vide discordant results that could influence epidemiological
studies. Consistent with this finding, three studies involving
more than 20 laboratories evaluating the reproducibility of
GBV-C RNA testing found surprisingly heterogeneous results,
even among laboratories using a commercial assay (5, 12, 13).
Because different testing methods for GBV-C viremia may
influence both the estimated prevalence and the estimates of
associations between GBV-C and HIV disease markers, we
studied three populations of HIV-infected individuals with sev-
eral primer sets in order to determine the optimal approach for
detecting GBV-C viremia.
(This work was presented in part at the International AIDS
Society meeting, 24 to 27 July 2005, in Rio de Janeiro, Brazil.)
MATERIALS AND METHODS
Patients. Three cohorts of HIV-infected subjects (939 subjects) were studied
to determine the sensitivities and specificities of test methods. Antiretroviral-
naive HIV-positive Brazilian patients (n  175) who participated in a previously
described, randomized, prospective antiretroviral clinical trial were retrospec-
tively studied (1, 25). The study participants were randomized to receive ART
between 1994 and 1996 with a single drug (indinavir; group 1), two drugs (zidovu-
dine and lamivudine; group 2), or three drugs (indinavir, zidovudine, and la-
mivudine; group 3). Demographic and clinical information and laboratory data
(including CD4 cell counts and plasma HIV RNA levels) were obtained as
previously described. The GBV-C RNA statuses of these patients were initially
determined using one set of primers (E2 region) in a study designed to investi-
gate the effect of GBV-C viremia on the response to antiretroviral therapy (25).
Another population of HIV-infected individuals (n  223) receiving care at the
University of Iowa HIV clinic who had sufficient samples stored for research
purposes were also studied. Patient characteristics have been previously de-
scribed (11, 36). A third cohort of HIV-infected women participating in the
Women’s Interagency HIV Study (WIHS) were also studied (1,082 samples from
541 HIV-positive women) using a limited set of primers based on a strategy
derived from the results of more extensive testing of the Brazilian and Iowa
cohorts. Informed consent was obtained from all participants, and the study was
approved by the University of Iowa Institutional Review Board.
GBV-C viremia and E2 antibody detection. Plasma or serum samples were
prepared as previously described and were stored at 70°C prior to this study
(25, 33). All samples were identified by a unique code, and laboratory personnel
were blinded to clinical data. To detect GBV-C viremia, RNA was extracted
from plasma using a previously described guanidinium-isothiocyanate extraction
method (the Brazilian cohort) (35) or a QIAamp Viral RNA Mini kit (the Iowa
and WIHS cohorts) according to the manufacturer’s instructions. RNA repre-
senting 25 l of plasma was used in nested RT-PCRs, and the RT-PCR ampli-
fication conditions and product identification were as previously described (35).
Five different sets of conserved oligonucleotide primers were designed based on
alignment of published GBV-C sequences (Table 1). Negative and positive
controls were included with each set of samples undergoing PCR testing.
Because it is not possible for RT-PCR testing with a single primer set to be
completely accurate, we developed stringent criteria to provide a working gold-
standard (GS) definition for GBV-C viremia. Because of limitations in sample
volume, four primer sets were used for the Brazilian cohort, whereas all five
primer sets were used for the University of Iowa cohort. Samples had to meet
one of the following criteria to meet the gold standard for GBV-C viremia. First,
samples that tested positive or negative with all primer sets were considered GS
positive or GS negative. For discordant samples to be considered positive for
GBV-C viremia, two samples from the same individual obtained on different
dates (within a 3-month window) had to reproducibly test positive by RT-PCR
using at least two different primer sets. While this is not an infallible classifica-
tion, it is a stringent definition which should be highly sensitive and specific.
All samples with GBV-C RNA detected using the 5-NTR primers were
TABLE 1. Oligonucleotide primer sequences utilized to detect GBV-C RNA
Region RT-PCR productsize (bp)a
GBV-C primer sequence
Outer Inner
5 NTR 204  AAGCCCCAGAAACCGACGCC CGGCCAAAAGGTGGTGGATG
 TGAAGGGCGACGTGGACCGT GTAACGGGCTCGGTTTAACG
E2b 745  GDC GYG AYT CGA ARA TMG AYG GATATCGAARATMGAYGTGTGGAG
 AAGATCAACGGGACCAGCCGTGCCTCA TTAGGTACCGCCTCAGCCAGCTTCAT
E2new
b 340  TGTGGGGTTCCGTDTCTTGGTT TGGNTCWGCCAGCTGYACCATAGC
 RAACGTHCCRCTVGGAGGCT DTCYCGGATCTTGGTCATGG
NS3 310  GGTRWCCCTTGATCCCACCAT TCGGCWGAAYTGTCGATGCA
 CACATBGTCCGCTGAAC ACGCCGCGHACYTTTGCCCA
NS5A 200  ATGGTYTAYGGYCCTGGVCAAA CTGGVCAAAGYGTYACCATT
 TACTGCARTCYTCCATGATGACAT TTCAAGAATCCTCGCAGCATTCT
5 NTRc  5 TACCGGTGTGAATAAGGGCC CTCGTCGTTAAACCGAGCCCGTCAd
 CGTCGTTTGCCCAGGTG
a Numbering is based on the sequence of the infectious GBV-C clone (GenBank accession number AF121950).
b E2 primers contain restriction endonuclease sites designed for previous studies.
c Primers used for real-time PCR experiments.
d Probe.
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quantified by one-step real-time PCR. RNA from 20 l of plasma was amplified
using 5-NTR primers and a 6-carboxyfluorescein/6-carboxytetramethylrhodamine-
labeled probe (Table 1) using the SuperScript II Platinum One-step Quantitative
RT-PCR System (Invitrogen) as recommended by the manufacturer. Specifically,
samples were amplified in an ABI Prism 7700 sequence detector, and the cycle
conditions were 50°C for 15 min and 95°C for 2 min, followed by 40 cycles of 58°C
for 15 s and 72°C for 1 min. A standard curve was generated using a positive
control sample containing 5  106 GBV-C genome equivalents (GE) per ml as
determined by repetitive terminal dilution analysis in nested RT-PCRs. GBV-C
antibodies against the envelope glycoprotein E2 were detected in serum or
plasma using an enzyme-linked immunosorbent assay method (Plate anti-
HGenv test; Roche Diagnostics GmbH, Penzberg, Germany) as recommended
by the manufacturer (28).
Data analysis. The prevalence of GBV-C viremia and the sensitivity, specific-
ity, and negative and positive predicted values (NPV and PPV) were estimated
for each RT-PCR test method (each primer set) based on results obtained on the
initial GBV-C RNA testing compared to the final assignment of GBV-C RNA
positive or negative based on the GS criteria described above.
For Brazilian subjects, the baseline HIV viral load (VL) (the RNA concen-
tration in genome equivalents per ml plasma) and CD4 T-cell count and the
average changes in the HIV VL and in the square root of the CD4 T-cell count
at weeks 24, 32, and 48 combined were analyzed according to the GBV-C viremia
status based on testing with each primer set. The baseline GBV-C VL was
measured in those who tested positive using the 5-NTR primer set. Multiple-
regression analysis, including the treatment effect, GBV-C viremia (yes/no),
GBV-C VL (for those positive by 5 NTR), baseline CD4 T-cell count, baseline
HIV VL, and other covariates (age, gender, transmission mode, CCR2, and
CCR5) (24), was used to examine the effects of these covariates on the change
in the HIV VL and CD4 T-cell counts in multivariate analyses as previously
described (25) (the baseline minus the average of weeks 24, 32, and 48 com-
bined). Because the lower limit of HIV RNA detection for the Brazilian cohort
was 500 copies per ml, a value of 0.5  log10 (500) copies/ml was imputed for
undetectable measurements of the HIV VL in the primary analysis (25) and
0.5  log10 (1,000) for an undetectable GBV-C VL. The GBV-C VL was also
categorized into high (106 copies/ml), low (106 copies/ml), and negative
(negative by GS). For the Iowa cohort, the HIV VL and CD4 T-cell count were
analyzed based on baseline data (upon entry into the clinic) and data from the
same day as the GBV-C testing, and a viral-load set point was determined (using
the median VL for each patient obtained when the patient was not receiving
antiretroviral medication).
Validation. Based on the results from the methods and analyses described
above, an algorithm with high sensitivity and specificity but simultaneously keep-
ing the number of RT-PCR tests small was developed and recommended for
clinical use. The algorithm was implemented on the 1,082 samples from the
WIHS, and the number of RT-PCRs required for implementation was recorded.
RESULTS
GBV-C viremia in the HIV-infected patient cohorts. Among
the Brazilian subjects studied, 37 (21.1%) had concordant pos-
itive results and 108 (61.71%) had concordant negative results
in RT-PCRs using all four sets of primers. Forty-nine subjects
(28.0%) had discrepant results when tested with different
primer sets. Sixteen of these subjects tested negative when E2
primers were used, yet GBV-C RNA was amplified by all three
of the other primer sets. In 5 of these 16 subjects, repeat testing
using the E2 primer set was positive. These subjects were by
definition GS GBV-C RNA positive. The overall estimated
prevalence of GBV-C viremia in this population was 30.3%
(53/175) based on the GS definition (see Materials and Meth-
ods). The rate of GBV-C viremia detection when samples were
tested with each of the four individual primer sets ranged from
21.1% to 38.3%. The PPV obtained using the E2 primer set
was 100% in this cohort, although the sensitivity was only
69.8%. The 5 NTR, NS5A, and NS3 primer pairs individually
or together detected all of the Brazilian subjects who were
classified as GBV-C RNA positive (GS). However, the speci-
ficities of these three primer sets were poor, only 89.3%,
90.9%, and 88.5%, respectively (Table 2).
To determine if the reason for the lower rate of detection
with the E2 primer set was related to a decrease in the sensi-
tivity of the assay, the end point dilution RNA detection was
determined for each primer set using a set of control samples.
The amount of RNA required for amplification by the E2
primer set was 16-fold greater than that required for the NS3
and NS5A primer sets and 8-fold higher than that required for
the 5-NTR primers (Fig. 1). Thus, the reduced rate of detec-
tion of GBV-C viremia by the E2 region primers appears to be
related to its reduced sensitivity, at least in part. An alternative
hypothesis is that the GBV-C E2 sequence differs significantly
between viruses infecting Brazilian subjects and subjects from
the United States, as the primers were previously tested in U.S.
populations. Consequently, we analyzed 223 subjects followed
in the University of Iowa HIV clinic. In addition to the four
sets of primers used to study the Brazilian cohort, we designed
and validated an additional set of primers from the E2 region
(E2new) (Table 1). The primer sequences were chosen based
on alignment of the E2 regions from 40 GBV-C isolates rep-
resenting all five GBV-C genotypes. In addition, the length of
the GBV-C genome that was amplified was shorter to improve
sensitivity. Using control samples, the sensitivities of these
primers were comparable to those of the 5-NTR primers.
Isolated discordant samples were retested under conditions
without reverse transcriptase in the reaction mixtures. These
samples were negative, suggesting that false-positive results
may not be related to carryover contamination of PCR prod-
ucts (data not shown).
FIG. 1. Sensitivities of GBV-C RNA detection using different
primer sets. RNA was extracted from GBV-C RNA positive control
serum. The control RNA template was diluted 1:800 (initial dilution
[1]) and in serial twofold dilutions as indicated. RT-PCR was per-
formed on each dilution using the four designated primer sets. The
NS3 and NS5A primers required 8- and 16-fold less RNA than did the
5-NTR and E2 primers (respectively) to amplify GBV-C RNA.
TABLE 2. GBV-C viremia prevalence and test characteristics for
combined Brazilian and U.S. cohorts (n  398)
Primer a Prevalence Sensitivity(%)
Specificity
(%) PPV NPV 
b
5 NTR 34.4 100 90.9 81.0 100 0.85
E2 21.4 76.6 100 100 91.7 0.83
E2new
c 22.4 79.4 97.6 92.0 93.1 0.80
NS3 34.7 88.3 86.1 71.0 95.0 0.69
NS5A 34.0 95.5 89.9 78.5 98.1 0.80
GS 27.9
a Primer set used to amplify GBV-C RNA.
b , kappa coefficient.
c Data only from U.S. (Iowa) cohort.
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Using these five primer sets to amplify GBV-C RNA from
samples from the subjects in the Iowa cohort, the estimated
prevalences ranged from 21.5% to 33.2% with individual prim-
ers, and using our GS definition, 26% were ultimately classified
as GBV-C viremic. Similar to the Brazilian cohort, the 5-NTR
primers were the most sensitive in amplifying GBV-C RNA;
however, the specificity was 92.1%, and the NS3 and NS5A
primers were less specific (82.4% and 90.9%, respectively).
The E2 primers remained 100% specific but did not detect
17.3% of the GBV-C RNA-positive individuals defined by the
GS criteria. Although the new primer set amplifying sequences
from the GBV-C E2 region (E2new) had an analytical sensitiv-
ity comparable to that of the 5-NTR primer set using the
control RNA preparation, these primers did not perform as
well as the original primers (sensitivity, 77.6%; specificity,
97.6%), suggesting that the reduced sensitivity with control
RNA preparations observed with the E2 primers does not
totally explain the poor sensitivity observed in the two cohorts
(Table 2). However, the fact that the new E2 primers did not
perform better than the original E2 primers, despite improved
sensitivity with control RNA, suggests that the reduced analyt-
ical performance of the E2 primers may be related to nucleo-
tide sequence variability in this region. Studies are under way
to address this hypothesis.
Combining the results from the Brazilian and Iowa cohorts,
GBV-C estimated prevalences ranged from 21.4% to 34.4%
when individual primers were used. The most specific primers
were those from the E2 region (100%), although the sensitivity
was only 76.6%. The most sensitive primers were those ampli-
fying the 5-NTR region (100%), although their specificity was
only 90.9%. The prevalence, sensitivity, specificity, and PPV
and NPV summary data for the combined Brazilian and U.S.
cohorts are shown in Table 2. Storage conditions may reduce
the quality of RNA in clinical samples with a resultant de-
crease in RT-PCR sensitivity. Thus, we compared GBV-C
prevalence results and VL values among the Iowa cohort sam-
ples stored for more than 5 years with those stored for less than
3 years and did not find any differences, suggesting that spec-
FIG. 2. Effect of primer selection on HIV RNA reduction following ART among 175 ART treatment-naı¨ve Brazilians. HIV RNA reductions
24, 36, and 48 weeks after initiation of ART were significantly (P 	 0.05) greater among GBV-C RNA-positive subjects than among GBV-C
RNA-negative subjects when tested with either the E2 or 5-NTR primer set and with the GS definition (see Materials and Methods). When
GBV-C RNA was detected by the NS3 and NS5A primers (which yielded higher rates of false-positive results), a greater reduction in HIV RNA
was also demonstrated; however, the results were no longer statistically significant at a P level of 	0.05.
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imen storage differences between samples did not significantly
influence our results (data not shown).
GBV-C viremia, clinical outcomes, and HIV surrogate mark-
ers. Because different primer sets yielded false-positive and
false-negative results, it is possible that misclassification of
GBV-C viremia based on the testing methods used might in-
fluence studies investigating potential associations between
GBV-C viremia and HIV clinical findings. To illustrate this
concern, we examined the effects of testing GBV-C RNA using
different primer sets on markers of HIV replication (HIV VL)
or pathogenesis (CD4 depletion) in the Brazilian and U.S.
HIV-infected populations. In contrast to some reports (14, 30),
no association was identified between the GBV-C VL and the
baseline HIV VL or baseline CD4 T-cell counts for the Bra-
zilian or Iowa populations, regardless of which primer set was
used (data not shown). However, HIV VL reduction following
initiation of their first ART regimen was greater in GBV-C
RNA-positive subjects than in GBV-C-negative Brazilians
(Fig. 2). The statistical significances of the results differed
depending upon which primer set was used. Specifically, when
GBV-C coinfection was determined by the E2 primers, 5-
NTR primers, or the gold-standard definition (PCR positive
with two or more primer sets), the reduction in HIV RNA was
statistically significant at P values of	0.05. However, using the
primer sets with low specificity (NS3 and NS5A) to determine
GBV-C viremia, the change in the HIV VL did not reach
statistical significance at the 0.05 level. Thus, not only did the
estimated rates of GBV-C viremia detection vary when differ-
ent primers were used, but the interpretation of the clinical-
outcome measurements also depended on which primer set
was used to detect GBV-C RNA.
GBV-C quantification. Quantification of GBV-C RNA in
the Brazilian cohort was performed using real-time RT-PCR,
and the average reduction in the HIV VL was studied in
relation to the GBV-C VL. Figure 3 demonstrates a relation-
ship between GBV-C VL and HIV VL reduction following
therapy. The effect of the GBV-C VL was well fitted by a linear
trend, with the log10 HIV VL reduction increasing by approx-
imately 0.24 copy/ml for a one-category increase (P  0.03).
The fit was not significantly improved by fitting a separate
effect for each category (P 0.74), and there was no significant
treatment by GBV-C category interaction (P  0.90).
Overall, GBV-C RNA levels ranged from 2.3  103 to 6.5 
108 GE per ml (Brazilian) and 6.5  108 to 5.8  108 GE/ml
(Iowa). The sensitivity of the real-time method was lower than
that of the nested-RT-PCR methods, and 6.5% of the GBV-C
RNA-positive subjects did not have detectable GBV-C RNA
using the real-time PCR method. A previously published Ger-
man study suggested a weak inverse correlation between the
GBV-C RNA concentration and the HIV RNA concentration
FIG. 3. Relationship between GBV-C RNA concentration and response to ART. The average reduction in HIV-RNA from baseline in the
Brazilian subjects (n 166) is shown when stratified by GBV-C RNA concentration. Subjects classified as GBV-C RNA negative using the criteria
defining the gold standard (neg) were compared with those with “low” GBV-C RNA concentrations (106 copies/ml GBV-C RNA) or “high”
GBV-C RNA concentrations (106 copies/ml). The estimated increased reduction in log HIV RNA for one category increase in GBV-C RNA
(neg  1, low  2, and high  3) was 0.236 copies/ml (P  0.03). Each box is between the upper and lower quartiles, with the bar denoting the
median. Hatched lines represent 2 deviations from the mean. The whiskers represent the largest and smallest datum points unless there are
outliers, which are shown as dots. Trt grp, treatment group.
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(R  0.33) (30), and another longitudinal study of HIV-
infected individuals found that the rate of the increase in HIV
VL was significantly lower over 5 to 6 years of follow-up in
GBV-C RNA-positive subjects than in GBV-C RNA-negative
subjects (33). However, a relationship between GBV-C and
HIV RNA levels was not observed at the pre-ART visit (Bra-
zilian) or at the viral set point (Iowa) (Fig. 4): the estimated
correlation coefficient was 0.01 (P  0.92), and a moderate-
to-large correlation was ruled out by the 95% confidence in-
terval (0.22 to 0.20). Similarly, in the Iowa cohort, the HIV
VL did not correlate with GBV-C RNA levels at baseline or on
the date of GBV-C RNA testing (data not shown).
Because the E2 primer set required a higher GBV-C titer in
order to amplify GBV-C RNA (Fig. 1), we compared the
GBV-C VLs among Brazilian subjects whose GBV-Cs were
classified based on the GS (E2 true-positive results) but who
were negative when tested with the E2 primer set (E2 false-
negative results). The Brazilians who tested negative with the
E2 primers had significantly lower GBV-C VLs (5.60 log10)
than those who tested positive with the E2 primers (6.47 log10;
P 0.039). This difference was more significant when the Iowa
cohort was analyzed, as the mean GBV-C VL among those
samples that were negative by the E2 primers was 1.68 log10
compared to 6.16 log10 among those positive by the E2 primers
(P 	 0.01).
GBV-C E2 antibody: prevalence and relationship to GBV-C
viremia. Each sample from the Brazilian and Iowa study sub-
jects was tested for antibody to the GBV-C envelope glyco-
protein (E2). Consistent with previous studies, the prevalence
of detection of antibody to the GBV-C E2 protein was high,
with E2 antibodies detected in 35% (136/391) of the entire
study population tested (25% of the Brazilians and 43% of the
U.S. cohort). Among those without GBV-C viremia, the over-
all rate of E2 antibody was 42% (Table 3). Evidence for expo-
sure to GBV-C (RNA or antibody) was less common in Bra-
zilians (54%) than in the U.S. cohort (63%). Concurrent
GBV-C viremia and E2 antibody detection was found in 12%
of the subjects. Among subjects with GBV-C infection as de-
fined by the GS criteria, the frequency of E2 antibody was
greater among those who tested negative for GBV-C RNA
using the E2 primer set (data not shown). The GBV-C VL was
lower among viremic individuals with E2 antibody (mean, log10
2.80 GE/ml versus log10 5.89 GE/ml; P  0.0001), suggesting
that E2 antibody indicates that subjects are in the process of
clearing GBV-C viremia or, perhaps, that these antibodies
select for less fit neutralization escape variants. Further studies
to address this question are under way.
DISCUSSION
As shown in previous studies, the estimated prevalence of
GBV-C viremia is high among HIV-positive individuals (30%
in the Brazilian study and 26% in the Iowa study). An addi-
tional 34% of the Brazilians and 51% of the Iowa cohort
without viremia had evidence of prior GBV-C infection (E2
antibody). Published GBV-C prevalences have relied upon
RT-PCR testing systems that amplify either the 5 NTR or the
E2, NS3, or NS5A region of the genome, and seldom have
samples been tested by more than one set of primers. In ad-
dition, the use of nested RT-PCR for amplification of clinical
samples is known to have problems with PCR carryover, lead-
ing to false-positive results. Thus, it is not too surprising that
previous quality assurance studies (5, 12, 13) found poor test
TABLE 3. GB virus C E2 antibody prevalence in the Brazilian and Iowa HIV-infected cohorts
GBV-C RNA status
GBV-C E2 antibody results
Brazil Iowa Combined
Negative Positive Negative Positive QNSa Negative Positive QNS
Positive 51 2 43 11 4 94 13 4
Negative 81 41 80 82 3 161 123 3
Total 132 43 123 93 7 255 136 7
a QNS, quantity not sufficient for testing.
FIG. 4. Relationship between baseline log10 GBV-C RNA cop-
ies/ml and detection by RT-PCR using the E2 primer set. The subjects
were those who were GBV-C RNA positive by the GS definition and
for whom log10 GBV-C RNA was available (n  97). A value of 0.5
log10 (1,000) was imputed for 1 Brazil and 18 Iowa subjects whose
GBV-C RNAs were below the lower limit of detection (*, P values
from two-sample t test, for each study; **, P value adjusted for study).
Each box is between the upper and lower quartile, with the bar de-
noting the median. The whiskers represent the largest and smallest
datum points.
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performance and significant variation between laboratories.
Although prior studies identified problems with the reproduc-
ibility of GBV-C RNA detection, these studies did not system-
atically determine the validity of their test results by using
multiple primer sets to amplify GBV-C RNA.
The E2 primer set resulted in the most specific detection of
GBV-C RNA (Table 2). However, this primer set proved to be
significantly less sensitive than the other four primer sets and
frequently did not detect GBV-C RNA in subjects with VLs
of	20,000 GE/ml. Nevertheless, these primers have been used
to detect GBV-C in studies of HIV-infected people (4, 25, 38),
and thus, some GBV-C-infected individuals were likely mis-
classified as GBV-C RNA negative. Testing positive with the
E2 primer set is a marker of high GBV-C VL, and if higher
GBV-C RNA concentrations are related to improved out-
comes in HIV-positive individuals, use of the E2 primer set
would increase the likelihood that a difference between
GBV-C viremic and nonviremic individuals would be detected.
This may explain the greater reduction in HIV VL among
Brazilian subjects positive for GBV-C by the E2 system than by
the other primer sets (Fig. 2), which is further supported by the
relationship between the GBV-C VL and treatment response.
Because the beneficial effect of zidovudine is transient due to
development of drug resistance and poor tolerability, achieving
a similar reduction in the HIV VL via infection with a non-
pathogenic virus that is constantly in the bloodstream, fre-
quently at high levels, strongly supports a clinically relevant
beneficial effect related to our observation.
Conversely, the 5 NTR, NS3, and NS5A primers appeared
to be overly sensitive (Table 2). Our data do not exclude the
possibility that the NS3 and NS5A primers may be accurate,
detecting very low levels of GBV-C RNA. To maximize ana-
lytical accuracy, samples testing only positive with one of these
primers were considered negative (by the gold-standard defi-
nition), and using these primers in clinical studies would dilute
any potential effect of GBV-C viremia on HIV disease markers
(Fig. 2). Using the E2, 5-NTR, and gold-standard criteria, the
reduction in HIV RNA following ART initiation was signifi-
cantly greater in those with GBV-C viremia (P  0.009, 0.04,
and 0.045, respectively), by approximately 0.5 log10, than in
those without GBV-C viremia, and there was a correlation
between the reduction in HIV VL following initiation of ART
and the GBV-C RNA concentration (Fig. 4). While the level of
HIV VL reduction seems modest and on an individual level
would not be significant, previous studies conclusively demon-
strated that for each 0.5 log10 copies/ml reduction in HIV VL
achieved with zidovudine monotherapy, the relative risk for
progression to AIDS was reduced by approximately 33% (P 	
0.001) (18). Because the beneficial effect of zidovudine is tran-
sient due to the rapid development of drug resistance, achiev-
ing a similar reduction in the HIV VL via infection with a
nonpathogenic virus that is constantly in the bloodstream
strongly supports a clinically relevant beneficial effect related
to our observation. While it is true that current combination
antiretroviral therapy is many times more potent, the additive
effect of a 0.5 log10 reduction is not trivial.
Unlike some studies (14, 30), we did not demonstrate a
higher baseline CD4 count or lower HIV RNA in those with
GBV-C viremia than in those without it in either the Brazilian
or the Iowa cohort. These data are limited by the fact that the
duration of HIV infection is not known for subjects who par-
ticipated in either of these studies. Furthermore, we also did
not detect an inverse relationship between the GBV-C VL and
the HIV VL (Fig. 4). Taken together, these data indicate that
GBV-C RNA quantification is not a critical measurement in
epidemiological studies of GBV-C and HIV disease progres-
sion but suggest that more accurate detection of viremia may
be necessary for optimal investigation of potential interactions
between these two virus infections.
These data suggest that neither RT-PCR detection of
GBV-C using any of the four primer sets individually nor
detection using the real-time RT-PCR method we used is suf-
ficient to accurately classify GBV-C viremia status in clinical
samples. Based on the sensitivity of the 5-NTR primer set, we
propose screening samples with these primers and testing
all positive samples again using the E2 primer set. Samples
testing positive with both sets of primers would be classified as
true positives, and discordant samples would be tested further.
Ideally, a new aliquot of the sample would be used to prepare
a new RNA, or if this was not available, the remaining RNA
from the first extraction would be used, and this RNA would be
tested with all four primer sets (5 NTR, E2, NS3, and NS5A).
Those with repeat positives of 5 NTR and positive by at least
one of the other two primer sets would be classified as positive.
Using this approach, we screened 1,082 samples from 541
women participating in the WIHS study, 21% of which (n 
231) tested positive by the 5-NTR primers. Among the 231
5-NTR-positive samples, 78% (n  180) tested positive with
the E2 primer set. Twenty-seven of the 51 discordant samples
tested negative when the NS3 and NS5A primer sets were
used. Thus, 204 of the 1,082 samples (19%) were classified as
positive using the gold-standard criteria, and a total of 1,517
RT-PCRs were required to test 1,082 samples. Unfortunately,
the sensitivity of the real-time RT-PCR method was poor, and
more than 10% of the samples that were positive by qualitative
RT-PCR were negative by real-time testing. Although the sen-
sitivity was poor, the specificity was excellent, with 98% of
positives confirmed by the nested-RT-PCR methods (data not
shown). The development of a more sensitive real-time
GBV-C RNA detection system is needed, and this may require
the use of multiplex real-time primers. Further, development
of an optimized real-time method would help decrease false-
positive results and would facilitate comparisons of data
among different laboratories.
In summary, these studies demonstrate that the primers
used to amplify GBV-C RNA in nested RT-PCRs provide high
rates of discordant results, and no one primer set consistently
provides accurate results. To be confident in RT-PCR detec-
tion of GBV-C RNA, amplification using at least two different
primer sets should be performed. Differences in the sensitivi-
ties and specificities of testing methods can affect epidemio-
logical studies, as shown by the difference in statistical signif-
icance of the HIV RNA reduction in the Brazilian cohort
following initiation of ART (Fig. 2). Finally, although a corre-
lation between the GBV-C VL and the HIV VL set point was
not observed, the plasma concentration of GBV-C RNA cor-
related with the extent of reduction in HIV RNA following
ART (Fig. 3), and subjects with the highest level of GBV-C
RNA had the greatest reduction in HIV RNA 48 weeks after
therapy was initiated.
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